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Live attenuated HIV vaccines cannot be tested in
humans because of their danger. Inactivated virions are
still dangerous and also poorly immunogenic. For that
reason subunit vaccines in one form or another have
been the approach of almost all investigators since 1984
when adequate HIV culture systems became available.
With the exception of using small animals for testing
immune responses all in vivo experimental vaccine test-
ing research utilize subhuman primates, especially maca-
ques, challenged with SIV or the chimeric SHIV (using
an HIV envelope with SIV). Thus, we begin with two
handicaps – a limitation to subunit vaccines and a lim-
itation in our animal model. However, the limits of the
animal model in my view are not due to any inadequacy
of the model but rather the limitation of monkeys. This
has been a problem from the beginning, but is one that
could have been overcome long ago with adequate
investments from funders. Instead, we witness most
quality investigators limited in their experiments to 4 to
6 animals per group, so as to require multiple repeated
experiments and years of delay, while a few groups can
afford 20 to 30 animals per group. Obviously, this needs
to change. A third handicap is HIV variation. Generally,
investigators have challenged macaques with homolo-
gous SIV (or SHIV), but this is inadequate. However, in
recent years the need for heterologous viral challenges
has finally been recognized. It would be ideal to chal-
lenge with several different heterologous challenges, but
there are serious limitations in available primate viral
stocks, particularly SHIV. The best protocol for testing a
candidate vaccine in macaques is controversial. Many
have favored a single relatively high dose challenge,
while recently several groups argue for multiple low
dose challenges. The fact is arguments can be made for
either, and no one knows which one will be more pre-
dictable for a HIV vaccine in man.
By far the greatest hurdle to an effective vaccine is the
retrovirus characteristics of HIV, namely its capacity to
rapidly integrate its genes into our DNA. This estab-
lishes life-long infection, rapid diminished function of
immune responses, and the emergence of variants. This
feature has major implications all too often forgotten in
the 1984 to 2008 period of HIV vaccine research,
namely an effective HIV vaccine: (1) must protect
against infection not just reduce HIV after infection; (2)
must be long lasting; and (3) must be broad.
Early in HIV vaccine history (roughly 1984-1990) the
candidate immunogen was focused on the gp120 envel-
ope delivered as protein, DNA, or vector with an HIV
env gene insert. Mostly these led to type specific
immune responses so vaccines of this type failed in the
monkey model when challenges were made with hetero-
logous strains of SIV or SHIV, especially with protein
alone. Nonetheless, a company (VaxGen) still went
forward with a gp120 protein clinical trial, and all too
predictably, completely failed, and caused much negativ-
ity for HIV vaccine research.
Many investigators then turned to CMI based vac-
cines. Though CMI is important and likely helpful to
any vaccine candidate, CMI alone is a predictable fail-
ure, and indeed such vaccines have failed (e.g., recent
NIAID – Merck trials in Africa).
We and some other groups think the answers will be
in finding, “fixing,” and properly presenting conserved
sequences of gp120 which are functionally required for
HIV infection. Finding conserved sequences is an
obvious need and a readily achievable one. “Fixing”
means making a constrained envelope because the
mobile envelope is a difficult and ever changing target.
We have chosen the CCR5 binding domains of gp120 as
the conserved and functionally necessary region. This
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region of gp120 contains novel epitopes called CD4i epi-
todes and Abs to them are known as CD4i Abs. We
approach this by linking gp120 to domains of CD4 that
bind gp120. We have developed a candidate vaccine
based on inducing CD4i Abs. These Abs are often
broadly reactive, and although we have not as yet
reached sterilizing immunity, the vaccine ultimately pro-
tects against a high dose heterologous challenge and
often has ADCC activity [1].
From our primate experiments and our studies in
human elite viral suppressors [2] we predict that a suc-
cessful HIV vaccine may consist of an immunogen that
induces CD4i Abs and ADCC type responses.
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